<DOC>
	<DOCNO>NCT00870155</DOCNO>
	<brief_summary>To obtain additional safety data subject previously complete MBP8298-01 study `` A Double Blind Placebo Controlled Multi-Centre Evaluate Efficacy Safety MBP8298 Subjects Secondary Multiple Sclerosis '' Dirucotide generic name MBP8298 .</brief_summary>
	<brief_title>A Study Patients With Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Multiple Sclerosis , Chronic Progressive</mesh_term>
	<criteria>1 . Subjects participate study must complete treatment require evaluation previous MBP829801 study `` A Double Blind Placebo Controlled MultiCentre Study Evaluate Efficacy Safety MBP8298 Subjects Secondary Progressive Multiple Sclerosis '' , 2 . Subject must able willing give meaningful , write informed consent prior participation trial accordance regulatory requirement , 3 . In Investigator 's opinion , subject must reliable , compliant agree cooperate trial evaluation . 1 . Use concomitant disease modify therapy Multiple Sclerosis e.g . ÃŸinterferon , glatiramer acetate mitoxantrone , cyclophosphamide , methotrexate , azathioprine , immunomodulating ( e.g . IVIG ) immunosuppressive drug include recombinant nonrecombinant cytokine . 2 . Any medical , psychiatric condition could result subject able give fully inform consent , comply protocol requirement . 3 . Any condition , Investigator 's opinion , make subject unsuitable participation study . 4 . Females breast feeding , pregnant use medically approve method contraception regularly .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2010</verification_date>
</DOC>